You are here: Industry Insights > adalimumab

News List

NHS to save £300 million by switching to Humira biosimilars pharmafile
November 28, 2018
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of AbbVie’s best-selling anti-inflammatory drug Humira (adalimumab)
Samsung and Bioepis launch third Humira biosimilar in Europe pharmafile
October 19, 2018
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) in Europe.
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access worldpharmanews
October 15, 2018
Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humi
Biogen, Samsung Bioepis and Abbvie settle patent dispute pharmatimes
July 18, 2018
Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.
Mylan, Biocon to launch Adalimumab Biosimilar in EU biospectrumasia
April 16, 2018
FKB’s product is at an advanced stage of review and could potentially obtain approval in Europe in the second half of 2018.
Novartis Advances Head-to-Head Superiority Trials of Cosentyx Versus Humira And Proposed Biosimilar biospace
January 10, 2018
Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS).
Adalimumab biosimilar exhibits same efficacy and safety for rheumatoid arthritis as originator pharmaceutical-journal
November 13, 2017
The trial data was presented at the American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting in San Diego, California by the manufacturers of Cyltezo.

Previous page 1 2 Next page